Showing posts with label Pills. Show all posts
Showing posts with label Pills. Show all posts

Friday, October 28, 2016

Spersatear




Spersatear may be available in the countries listed below.


Ingredient matches for Spersatear



Hypromellose

Hypromellose is reported as an ingredient of Spersatear in the following countries:


  • South Africa

International Drug Name Search


Posted by at No comments:
Labels:

Dapson PCH




Dapson PCH may be available in the countries listed below.


Ingredient matches for Dapson PCH



Dapsone

Dapsone is reported as an ingredient of Dapson PCH in the following countries:


  • Netherlands

International Drug Name Search


Posted by at No comments:
Labels:

Nor-Q. D




Ingredient matches for Nor-Q.D.



Norethisterone

Norethisterone is reported as an ingredient of Nor-Q.D. in the following countries:


  • United States

International Drug Name Search


Posted by at No comments:
Labels:

Juvenile Rheumatoid Arthritis Medications


Definition of Juvenile Rheumatoid Arthritis: A chronic, inflammatory disease that may cause joint or connective tissue damage. The onset occurs before age 16.

Drugs associated with Juvenile Rheumatoid Arthritis

The following drugs and medications are in some way related to, or used in the treatment of Juvenile Rheumatoid Arthritis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Juvenile Rheumatoid Arthritis

  • Juvenile Idiopathic Arthritis (5 drugs)

  • Still's Disease (2 drugs)

Learn more about Juvenile Rheumatoid Arthritis

Medical Encyclopedia:

  • Juvenile rheumatoid arthritis




Drug List:


Posted by at No comments:
Labels:

Thursday, October 27, 2016

Copaxone


Copaxone is a brand name of glatiramer, approved by the FDA in the following formulation(s):


COPAXONE (glatiramer acetate - injectable; subcutaneous)



  • Manufacturer: TEVA

    Approval date: February 12, 2002

    Strength(s): 20MG/ML [RLD]

Has a generic version of Copaxone been approved?


No. There is currently no therapeutically equivalent version of Copaxone available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Copaxone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Copolymer-1 improvements in compositions of copolymers
    Patent 5,981,589
    Issued: November 9, 1999
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,054,430
    Issued: April 25, 2000
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,342,476
    Issued: January 29, 2002
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research & Development Company Limited
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE




  • Copolymer-1 improvements on compositions of copolymers
    Patent 6,362,161
    Issued: March 26, 2002
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research & Development Company Limited
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,620,847
    Issued: September 16, 2003
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Drug substance




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,939,539
    Issued: September 6, 2005
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research & Development
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Drug substance




  • Copolymer-1 improvements in compositions of copolymers
    Patent 7,199,098
    Issued: April 3, 2007
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Drug substance



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 27, 2012 - INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS

See also...

  • Copaxone Consumer Information (Drugs.com)
  • Copaxone Consumer Information (Wolters Kluwer)
  • Copaxone injection Consumer Information (Cerner Multum)
  • Copaxone Advanced Consumer Information (Micromedex)
  • Copaxone AHFS DI Monographs (ASHP)
  • Glatiramer Consumer Information (Wolters Kluwer)
  • Glatiramer injection Consumer Information (Cerner Multum)
  • Glatiramer Subcutaneous Advanced Consumer Information (Micromedex)
  • Glatiramer Acetate AHFS DI Monographs (ASHP)

Posted by at No comments:
Labels:

Nifedipine PCH




Nifedipine PCH may be available in the countries listed below.


Ingredient matches for Nifedipine PCH



Nifedipine

Nifedipine is reported as an ingredient of Nifedipine PCH in the following countries:


  • Netherlands

International Drug Name Search


Posted by at No comments:
Labels:

Somatulina Autogel




Somatulina Autogel may be available in the countries listed below.


Ingredient matches for Somatulina Autogel



Lanreotide

Lanreotide acetate (a derivative of Lanreotide) is reported as an ingredient of Somatulina Autogel in the following countries:


  • Portugal

  • Spain

International Drug Name Search


Posted by at No comments:
Labels:

Olina




Olina may be available in the countries listed below.


Ingredient matches for Olina



Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Olina in the following countries:


  • Dominican Republic

International Drug Name Search


Posted by at No comments:
Labels:

Simvabeta




Simvabeta may be available in the countries listed below.


Ingredient matches for Simvabeta



Simvastatin

Simvastatin is reported as an ingredient of Simvabeta in the following countries:


  • Germany

International Drug Name Search


Posted by at No comments:
Labels:

Salocin




Salocin may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Salocin



Salinomycin

Salinomycin sodium salt (a derivative of Salinomycin) is reported as an ingredient of Salocin in the following countries:


  • United Kingdom

International Drug Name Search


Posted by at No comments:
Labels:

Oxaliplatin Winthrop




Oxaliplatin Winthrop may be available in the countries listed below.


Ingredient matches for Oxaliplatin Winthrop



Oxaliplatin

Oxaliplatin is reported as an ingredient of Oxaliplatin Winthrop in the following countries:


  • Czech Republic

  • Denmark

  • Germany

  • Slovenia

  • Sweden

International Drug Name Search


Posted by at No comments:
Labels:

Wednesday, October 26, 2016

Vitamine B12 Allergan




Vitamine B12 Allergan may be available in the countries listed below.


Ingredient matches for Vitamine B12 Allergan



Cyanocobalamin

Cyanocobalamin is reported as an ingredient of Vitamine B12 Allergan in the following countries:


  • France

International Drug Name Search


Posted by at No comments:
Labels:

Dermasil




Dermasil may be available in the countries listed below.


Ingredient matches for Dermasil



Terbinafine

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Dermasil in the following countries:


  • Israel

International Drug Name Search


Posted by at No comments:
Labels:

Zorkaptil




Zorkaptil may be available in the countries listed below.


Ingredient matches for Zorkaptil



Captopril

Captopril is reported as an ingredient of Zorkaptil in the following countries:


  • Serbia

International Drug Name Search


Posted by at No comments:
Labels:

Xyzal


Xyzal is a brand name of levocetirizine, approved by the FDA in the following formulation(s):


XYZAL (levocetirizine dihydrochloride - solution; oral)



  • Manufacturer: UCB INC

    Approval date: January 28, 2008

    Strength(s): 2.5MG/5ML [RLD][AA]

XYZAL (levocetirizine dihydrochloride - tablet; oral)



  • Manufacturer: UCB INC

    Approval date: May 25, 2007

    Strength(s): 5MG [RLD][AB]

Has a generic version of Xyzal been approved?


A generic version of Xyzal has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Xyzal and have been approved by the FDA:


levocetirizine dihydrochloride solution; oral



  • Manufacturer: SYNTHON PHARMS

    Approval date: November 7, 2011

    Strength(s): 2.5MG/5ML [AA]

levocetirizine dihydrochloride tablet; oral



  • Manufacturer: DR REDDYS LABS LTD

    Approval date: February 24, 2011

    Strength(s): 5MG [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: February 24, 2011

    Strength(s): 5MG [AB]


  • Manufacturer: SYNTHON PHARMS

    Approval date: November 26, 2010

    Strength(s): 5MG [AB]


  • Manufacturer: TEVA PHARMS

    Approval date: August 22, 2011

    Strength(s): 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xyzal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Methods for treating allergic disorders using optically pure (-) cetirizine
    Patent 5,698,558
    Issued: December 16, 1997
    Inventor(s): Gray; Nancy M.
    Assignee(s): Sepracor, Inc.
    Methods are disclosed utilizing optically pure (-) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma.
    Patent expiration dates:

    • September 24, 2012
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS


    • September 24, 2012
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS


    • March 24, 2013
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • November 25, 2010 - PEDIATRIC EXCLUSIVITY

    • August 21, 2012 - NEW PATIENT POPULATION

    • February 21, 2013 - PEDIATRIC EXCLUSIVITY

See also...

  • Xyzal Consumer Information (Drugs.com)
  • Xyzal Consumer Information (Wolters Kluwer)
  • Xyzal Solution Consumer Information (Wolters Kluwer)
  • Xyzal Consumer Information (Cerner Multum)
  • Xyzal Advanced Consumer Information (Micromedex)
  • Xyzal AHFS DI Monographs (ASHP)
  • Levocetirizine Consumer Information (Wolters Kluwer)
  • Levocetirizine Solution Consumer Information (Wolters Kluwer)
  • Levocetirizine Consumer Information (Cerner Multum)
  • Levocetirizine Advanced Consumer Information (Micromedex)
  • Levocetirizine Dihydrochloride AHFS DI Monographs (ASHP)

Posted by at No comments:
Labels:

Nisidol




Nisidol may be available in the countries listed below.


Ingredient matches for Nisidol



Nefopam

Nefopam hydrochloride (a derivative of Nefopam) is reported as an ingredient of Nisidol in the following countries:


  • Vietnam

International Drug Name Search


Posted by at No comments:
Labels:

Diproforte




Diproforte may be available in the countries listed below.


Ingredient matches for Diproforte



Betamethasone

Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Diproforte in the following countries:


  • Austria

International Drug Name Search


Posted by at No comments:
Labels:

Sinobid




Sinobid may be available in the countries listed below.


Ingredient matches for Sinobid



Norfloxacin

Norfloxacin is reported as an ingredient of Sinobid in the following countries:


  • Greece

International Drug Name Search


Posted by at No comments:
Labels:

Zil




Zil may be available in the countries listed below.


Ingredient matches for Zil



Ornidazole

Ornidazole is reported as an ingredient of Zil in the following countries:


  • India

International Drug Name Search


Posted by at No comments:
Labels:

Vertigen




Vertigen may be available in the countries listed below.


Ingredient matches for Vertigen



Betahistine

Betahistine is reported as an ingredient of Vertigen in the following countries:


  • Colombia

Betahistine dihydrochloride (a derivative of Betahistine) is reported as an ingredient of Vertigen in the following countries:


  • Poland

International Drug Name Search


Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)